Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)

被引:2
|
作者
Pothuri, Vikram [1 ]
Rodriguez, Jorge G. Zarate [1 ]
Kasting, Christina [1 ]
Leigh, Natasha [1 ,2 ]
Hawkins, William G. [1 ,2 ]
Sanford, Dominic E. [1 ,2 ]
Fields, Ryan C. [1 ,2 ,3 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Alvin J Siteman Comprehens Canc Ctr, Sch Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave Campus Box 8109, St Louis, MO 63110 USA
关键词
RACIAL DISPARITIES; CANCER;
D O I
10.1016/j.hpb.2023.08.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The impact of neighborhood deprivation on outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) is not well-described and represents an area to improve disparities.Methods: We retrospectively queried our prospectively maintained database of patients with PDAC (2014-2022). Patients were grouped by Area Deprivation Index (ADI) and rural-urban commuting area (RUCA) codes. Cox proportional hazards models and logistic regressions were used to investigate effect on overall survival (OS) and adjuvant therapy administration.Results: 536 patients were included. High ADI patients (more disadvantaged, n = 184) were more likely to identify as non-Hispanic Black (17.9% vs. 4.8%, p < 0.01) and were more likely to be from rural areas (49.5% vs. 18.5%, p < 0.01). High ADI was independently associated with decreased OS (HR (95% CI): 1.31 (1.01-1.69), p = 0.04). Urban high ADI patients were 3.5 times more likely to receive adjuvant therapy than rural high ADI patients (OR [95% CI]: 3.48 [1.26-9.61], p = 0.02).Conclusion: Patients from the most disadvantaged neighborhoods have decreased OS. Access to adjuvant therapy likely contributes to this disparity in rural areas. Investigation into sources of this OS disparity and identification of barriers to adjuvant therapy will be crucial to improve outcomes in un-derserved patients with PDAC.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 50 条
  • [31] NEOADJUVANT THERAPY-INDUCED SARCOPENIA IS ASSOCIATED WITH DECREASED OVERALL SURVIVAL IN PANCREATIC DUCTAL ADENOCARCINOMA
    Sell, Naomi M.
    Fernandez-del Castillo, Carlos
    Ferrone, Cristina R.
    Lillemoe, Keith
    Hank, Thomas P.
    Weekes, Colin D.
    Torriani, Martin
    Buckless, Colleen G.
    Silver, Julie K.
    Fintelmann, Florian J.
    Qadan, Motaz
    GASTROENTEROLOGY, 2020, 158 (06) : S1527 - S1528
  • [32] Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma
    Macfie, Rebekah
    Berger, Yael
    Liu, Hongdau
    Li, Thomas
    Imtiaz, Sayed
    Ang, Celina
    Sarpel, Umut
    Hiotis, Spiros
    Labow, Daniel
    Golas, Benjamin
    Cohen, Noah A.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (8) : 5027 - 5034
  • [33] Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma
    Rebekah Macfie
    Yael Berger
    Hongdau Liu
    Thomas Li
    Sayed Imtiaz
    Celina Ang
    Umut Sarpel
    Spiros Hiotis
    Daniel Labow
    Benjamin Golas
    Noah A. Cohen
    Annals of Surgical Oncology, 2023, 30 : 5027 - 5034
  • [34] Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
    Pugalenthi, Amudhan
    Protic, Mladjan
    Gonen, Mithat
    Kingham, T. Peter
    Angelica, Michael I. D'.
    Dematteo, Ronald P.
    Fong, Yuman
    Jarnagin, William R.
    Allen, Peter J.
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (02) : 188 - 193
  • [35] The impact of a history of cancer on pancreatic ductal adenocarcinoma survival
    He, Xingkang
    Li, Yue
    Su, Tingting
    Lai, Sanchuan
    Wu, Wenrui
    Chen, Luyi
    Si, Jianmin
    Sun, Leimin
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (06) : 888 - 894
  • [36] The Addition of Radiation Therapy to Adjuvant Chemotherapy is Associated With Improved Overall Survival in Resected Pancreatic Adenocarcinoma
    Rutter, C. E.
    Park, H. S. M.
    Corso, C. D.
    Lester-Coll, N. H.
    Mancini, B. R.
    Yeboa, D. N.
    Johung, K. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S154 - S155
  • [37] Adjuvant therapy (Adj) in intraductal papillary mucinous neoplasm cancer (IPMN-Ca) versus pancreatic ductal adenocarcinoma (PDAC): Comparison of survival analyses.
    Krishna, Kavya
    Krishna, Somashekar Gopala
    Bloomston, Mark
    Muscarella, Peter
    Schmidt, Carl Richard
    Conwell, Darwin
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Association of Adjuvant Chemotherapy with Overall Survival in Resected Pancreatic Adenocarcinoma Previously Treated with Neoadjuvant Therapy
    Swords, D. S.
    Garrido-Laguna, I.
    Mulvihill, S. J.
    Stoddard, G. J.
    Firpo, M. A.
    Scaife, C. L.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S116 - S116
  • [39] A model for defining molecular aspects of pancreatic ductal adenocarcinoma patients for targeted adjuvant therapy
    Showalter, Shayna L.
    Witkiewicz, Agnes
    Cozzitorto, Joseph A.
    Sauter, Patricia K.
    Kennedy, Eugeen P.
    Yeo, Charles J.
    Brody, Jonathan R.
    GASTROENTEROLOGY, 2008, 134 (04) : A913 - A913
  • [40] PRESENTING SYMPTOMS, TIME TO DIAGNOSIS, AND TIME TO REFERRAL CENTER CONSULTATION SIGNIFICANTLY CORRELATE WITH OVERALL SURVIVAL (OS) IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): A COHORT OF 671 PATIENTS
    Dedeilia, Aikaterini
    Kalina, Stephen
    Ballian, Nikiforos
    Tsiotos, Grigorios
    GASTROENTEROLOGY, 2024, 166 (05) : S1906 - S1906